Table 3

Number and percentage of patients at each follow-up on different treatments and smoking status, stratified by cohort

Follow-up assessment
01235710
Patients at assessment
 Cohort 1, n1022948875832780626607
 Cohort 2, n631588530533498407340
Smoking status
Cohort 1
 Never, n (%)323 (31.6)302 (31.9)281 (32.1)265 (31.9)252 (32.3)204 (32.6)193 (31.8)
 Ex-smoker, n (%)424 (41.5)416 (43.9)392 (44.8)385 (46.4)361 (46.3)288 (46.0)287 (47.3)
 Current, n (%)274 (26.8)229 (24.2)202 (23.1)180 (21.7)167 (21.4)134 (21.4)127 (20.9)
Cohort 2
 Never, n (%)233 (37.1)218 (37.2)201 (38.1)203 (38.2)195 (39.2)157 (38.7)134 (39.5)
 Ex-smoker, n (%)252 (40.1)244 (41.6)225 (42.6)231 (43.5)211 (42.5)186 (45.8)161 (47.5)
 Current, n (%)143 (22.7)124 (21.2)102 (19.3)97 (18.3)91 (18.3)63 (15.5)44 (12.9)
sDMARD*
 Cohort 1, n (%)153 (15.0)276 (29.1)274 (31.3)269 (32.3)239 (30.6)207 (33.1)195 (32.1)
 Cohort 2, n (%)278 (44.1)356 (60.5)327 (61.7)321 (60.2)288 (57.8)256 (62.9)209 (61.5)
Methotrexate
 Cohort 1, n (%)12 (1.2)56 (5.9)73 (8.3)93 (11.2)116 (14.9)120 (19.8)129 (21.3)
 Cohort 2, n (%)186 (29.5)251 (42.7)231 (43.6)231 (43.3)209 (42.0)196 (48.2)163 (47.9)
bDMARD*
 Cohort 1, n (%)0 (0)0 (0)0 (0)0 (0)0 (0)1 (0.2)11 (1.8)
 Cohort 2, n (%)2 (0.3)5 (0.9)17 (3.2)19 (3.6)27 (5.4)29 (7.1)40 (11.8)
Oral steroids
 Cohort 1, n (%)78 (7.6)113 (11.9)109 (12.5)111 (13.3)93 (11.9)70 (11.2)66 (10.9)
 Cohort 2, n (%)132 (20.9)124 (21.1)96 (18.1)91 (17.1)83 (16.7)63 (15.5)39 (11.5)
  • Percentages are given as a percentage of the number of patients in the corresponding cohort at the corresponding follow-up.

  • *sDMARDs included intramuscular gold salts, penicillamine, sulfasalazine, (hydroxy)chloroquine, methotrexate, azathioprine, cyclophosphamide and leflunomide. bDMARDs included etanercept, infliximab, adalimumab and rituximab.

  • bDMARD, biologic disease-modifying antirheumatic drug; sDMARD, synthetic disease-modifying antirheumatic drug.